Agios Pharmaceuticals Q3 2016 Financial Results

Agios Pharmaceuticals presented third quarter 2016 financial results on November 3, 2016, detailing clinical development progress for IDH1/IDH2 and pyruvate kinase-R mutation therapies including enasidenib (AG-221), AG-120, AG-881, AG-348, and AG-519. The presentation covers financial performance, clinical milestones, and forward-looking guidance for cash position and drug development timelines.